cutting edge knowledge about molecular medicine from the human genome through to clinical and therapeutic strategies
We evaluate next-generation biomedical data and provide high value connections between three key areas; basic laboratory research findings, clinical medicine and corporate enterprises. These analyses allow our clients to leverage their improved understanding of the latest knowledge stemming from the human genome through to clinical and therapeutic implementation. Our extensive network of medical, research, business and legal Affiliates provides specialist input.
We integrate data from information sources between which data transfer is slow and fragmented; researchers focussed on laboratory discoveries, physicians busy with treating patients for a broad spectrum of human conditions, biotechnology companies developing novel diagnostic technologies and corporations evaluating their future product lines. Our areas of analysis include; genetics, epigenetics, cancer therapeutics, drugs, stem cells, pathologies of human diseases, renal healthcare, personalized medicine and diagnostic nanotechnologies.
We do not accept Federal or State government funds.
We do not accept grants, gifts or gratuities from drug companies.
We do not hold shares in the companies on which we perform due diligence.
We believe that primary clinical data are the gold standard.